Physician profile
Barry M Lifschitz
NPI 1457413031
$14,110.32
in general payments reported to CMS, 2019-2025
25 companies · $391 in 2025
The $391 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $69.23 · 2022: $160 · 2023: $443 · 2024: $438 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,272.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $11,999.84 | 2019 | |
| Abbvie INC. | $233.90 | 2019-2025 | |
| Abbott Laboratories | $228.25 | 2022-2024 | Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.10 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $168.80 | 2019-2025 | |
| Corcept Therapeutics | $163.88 | 2019-2024 | Korlym |
| Novo Nordisk INC | $155.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $124.81 | 2019-2024 | Jardiance |
| Radius Health, INC. | $115.18 | 2024-2025 | Tymlos |
| Astrazeneca Pharmaceuticals Lp | $112.88 | 2019-2020 | |
| Mannkind Corporation | $102.48 | 2019-2023 | Afrezza |
| Pfizer INC. | $81.56 | 2019-2025 | |
| Ascendis Pharma Endocrinology INC | $48.72 | 2024-2025 | Yorvipath |
| Horizon Therapeutics Plc | $48.43 | 2023 | Tepezza |
| Becton, Dickinson and Company | $45.29 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $41.69 | 2024-2025 | Evenity, Repatha |
| Astellas Pharma US INC | $40.33 | 2023-2024 | Veozah |
| Kyowa Kirin, INC. | $29.15 | 2025 | |
| Insulet Corporation | $26.01 | 2019-2020 | |
| Dexcom, INC. | $24.03 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.90 | 2019 | |
| Chiesi USA, INC. | $22.41 | 2025 | Mycapssa |
| Aytu Biopharma, INC. | $20.16 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.34 | 2023 | |
| Amneal Pharmaceuticals LLC | $16.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Lifschitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.